U-PLEX®

Human Glucagon



a

www.mesoscale.com®

Ordering Information

MSD Customer Service
Phone: 1-240-314-2795
Fax: 1-301-990-2776
Email: CustomerService@mesoscale.com

Scientific Support

Phone: 1-240-314-2798
Email: ScientificSupport@mesoscale.com

Company Address

Meso Scale Discovery
A division of
Meso Scale Diagnostics, LLC.
1601 Research Boulevard
Rockville, MD 20850-3173 USA

Product Options	Catalog Number	Description
Multiplex	K151ACM, K251ACM	U-PLEX Metabolic Group 1 (human)
Singleplex	K1515YK-1/-2/-4	U-PLEX Human Glucagon Assay with SECTOR™ plates
	K1515YK-21/-22/-24	U-PLEX Human Glucagon Assay with QuickPlex Ultra™ plates
	K2515YK-2/-4	U-PLEX Glucagon Assay with 384-well plates
Antibody Set	B215Y-2/-3	U-PLEX Human Glucagon Antibody Set
Protocol	U-PLEX Product Inserts are available at www.mesoscale.com	

The MESO SCALE DISCOVERY® U-PLEX platform was designed to provide ultimate flexibility for detection of biomarkers in a wide variety of sample types. This datasheet provides the representative performance of the U-PLEX® Human Glucagon Assay tested on U-PLEX 96-well SECTOR plates run as a multiplex. The data do not represent the product specifications. Under your experimental conditions, the assay may perform differently from the representative data. U-PLEX assays are offered in either singleplex or multiplex; both are available on 96- or 384-well plates. See a U-PLEX product insert for instrument compatibility.

Representative Calibration Curve and Sensitivity



Assay	Median LLOD (pM)	LLOD Range (pM)
Glucagon	0.13	0.12-0.21

The Calibrator curve was fitted with a 4-parameter logistic model with a $1/Y^2$ weighting. The lower limit of detection (LLOD) is a calculated concentration corresponding to 2.5 standard deviations above the background (zero Calibrator).

Precision

Control	Average Conc. (pM)	Average Intra-run Conc. (%CV)	Inter-run Conc. (%CV)
High	56	4.5	11.9
Mid	12	4.0	13.4
Low	2.5	11.5	17.1

Controls were made by spiking Calibrator into assay diluent at 3 levels within the quantitative range of the assay. Average intra-run concentration %CV is the average %CV of the control replicates within an individual run. Inter-run concentration %CV is the variability of controls across multiple runs.

MSD® U-PLEX Human Glucagon

Tested Samples

Sample Type	Serum (N=12)	EDTA Plasma (N=12)	P800 Plasma (N=8)
Median (pM)	0.87	0.42	6.4
Range (pM)	ND-1.5	ND-3.0	3.9-9.6
% Detected	33	75	100

Normal serum, EDTA plasma, and P800 plasma samples were diluted 4-fold prior to the assay. ND = non-detectable (<LLOD)

Dilution Linearity

Serum			EDTA Plasma			P800 Plasma			Cell Culture Media		
Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range
2	104	77-131	2	114	87-147	2	113	100-151	2	116	106-134
8	96	86-109	8	93	72-101	8	93	84-110	8	95	83-110
16	103	76-141	16	95	74-116	16	98	80-121	16	92	75-112

Normal human serum, EDTA plasma, P800 plasma, and cell culture media were spiked with Calibrator and tested at different dilutions. Percent recovery at each dilution level was normalized to the dilution-adjusted, 4-fold concentration. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

Spike Recovery

	Serum		EDTA Plasma		P800 Plasma		Cell Culture Media	
Spike Level	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range
High	104	90-114	112	99-121	102	98-105	105	91-112
Mid	101	88-108	110	102-122	100	96-105	100	84-114
Low	99	89-106	110	100-126	100	99-102	97	72-109

Normal serum, EDTA plasma, P800 plasma, and cell culture media were spiked with Calibrator at 3 levels. Spiked samples were diluted 4-fold to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

Specificity

To assess specificity, the Glucagon Antibody Set was tested individually against a larger panel of analytes for nonspecific binding (BAFF, BDNF, C-Peptide, CTACK, Desghrelin, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, FGF-21, FGF-23, FLT3L, Fractalkine, FSH, G-CSF, Ghrelin (Ser3-octanoylated), GIP (1–42), GIP (3–42), GLP-1 (7–36), GLP-1 (9–36), GM-CSF, GRO-α, I-309, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, Insulin, IP-10, I-TAC, Leptin, LH, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-1β, MIP-5, PP, Proinsulin, PYY (3-36), SDF-1α, TNF-α, TNF-β, TPO, TRAIL, TSLP, VEGF-A, YKL-40, and β-NGF). Nonspecific binding was less than 2.0%.

% Nonspecificity = (nonspecific signal / specific signal) x 100

Diluent Compatibility

The data included in this document were collected with Assay Diluent 13 (supplemented with 1,000 KIU/mL Aprotinin [provided] and 100 µM diprotin A [not provided]) and Antibody Diluent 11. MSD offers a range of assay and antibody diluents for separate purchase. Depending on your assay needs, other diluents may be tested. Diprotin A should be purchased separately.

Assay Components

Calibrator: Glucagon is included in Calibrator 13. The human Glucagon Calibrator is a full-length recombinant protein expressed in *E. coli*.
Antibodies: The U-PLEX Human Glucagon Assay uses a mouse monoclonal antibody for capture and a mouse monoclonal antibody for detection.
Assay generation: B

Note: This datasheet contains representative assay performance data. In custom multiplex formats, the assay may perform differently from the representative data shown.